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Cancer  therapy has  been developed in  the las t  several  decades from non-specif ic  
cytotoxic  chemotherapy to  specif ic  targeted therapeutics .  One of  the  most  important  
progressions in  melanoma therapy is  the  discovery of  BRAF inhibi tors ,  including 
vemurafenib,  which led to  s ignif icant  c l in ical  responses  in  melanoma.  However ,  i t  
fa i ls  to  eradicate  tumors  in  nearly  a l l  pat ients  due to  short- l ived responses and drug 
resis tance,  and almost  a l l  pat ients  eventual ly  re lapse.  Therefore ,  novel  s t ra tegies  
are  s t i l l  required for  melanoma therapy.   
    Defect ive apoptosis  in  cancers  can impair  c l in ical  responses  to  ant i-cancer  
therapy.  Pro-apoptot ic  BCL-2 proteins ,  BAX and BAK, are  known as  cr i t ical  
effectors  for  in tr insic  apoptosis ;  however ,  how BAX and BAK cooperate  to  
determine cel l  death  are  s t i l l  remain unclear  and their  roles  are  overlapping or  
redundant .  In  this  s tudy,  I  h ighl ight  that  act ivat ion of  both BAX and BAK 
contr ibute  to  cancer  cel l  death  induced by many apoptot ic  s t imulat ion.  A bet ter  
understanding of  BAX/BAK dependency of  each ant i-cancer  reagent  might  be 
helpful  to  determine more effect ive response in  cancer  therapy.  
 
Chapter  1 .  Coptidis  Rhizoma induces intr insic  apoptosis  through BAX and BAK 
act ivat ion in  human melanoma（論文 1）  
Tradi t ional  herbal  medicines  have been found to  have ant i-cancer  effects  in  
var ious types of  cancer  including melanoma in  recent  years .  In  chapter  1 ,  I  
determined that  a  t radi t ional  herbal  medicine,  Coptidis  Rhizoma water  extracts  
	
(CR),  suppressed melanoma cel l  growth thorough apoptosis ,  which was regulated by 
the suppression of  MCL1, BCL2A1 and BCL-w, resul t ing in  the  act ivat ion of  
BAX/BAK. CR or  some formulat ions containing CR, may be effect ive and safe  
t reatment  s t ra tegies  for  melanoma.   
 
Chapter  2 .  Rat ional  combinat ion therapy for  melanoma with  CDK2/9 inhibi t ion by 
target ing BAK-dependent  cel l  death（論文 2）  
BRAF inhibi tor ,  vemurafenib,  is  widely used to  t reat  melanoma pat ients  as  
monotherapy or  in  combinat ion in  c l inical  therapeutics .  Vemurafenib has  been 
reported to  induce modest  apoptosis  in  melanoma cel ls ;  however ,  the  mechanism 
underlying i t  has  been well  understood yet .  In  chapter  2 ,  I  demonstrated that  BAX is  
indispensable  for  BRAF/MEK inhibi tor- induced melanoma apoptosis .  After  the  
screening of  chemotherapeutic  agent  l ibrary,  I  found two CDK2/9 inhibi tors ,  
d inacicl ib  and iCDK2/9,  as  the  drugs inducing apoptosis  a t  a  BAK-dependent  
manner  through MCL1 reduct ion.  Although vemurafenib with  MEK inhibi tor ,  
t rametinib ,  could not  s t rongly suppress  cel l  growth in  vi t ro ,  the  combinat ion of  
dinacicl ib  with  BAX-act ivat ing drugs synergis t ical ly  inhibi ted melanoma growth in  
vi t ro  and in  vivo.  Final ly ,  I  proposed a  ra t ional  combinat ion of  BAK-dependent  
CDK2/9 inhibi tor  with  BAX-dependent  drugs,  such as  BRAF/MEK inhibi tor ,  might  
be an at t ract ive s tra tegy for  t reat ing melanoma,  proposing the novel  theory to  
determine the ra t ional  combinat ion using two molecular- targeted drugs act ivat ing 
ei ther  BAK or  BAX, respect ively .  
 
    Collect ively ,  these s tudies  present  the  potent ia l  use  of  target ing BAX/BAK as 
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